Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

Core Viewpoint - W.R. Berkley Corporation (WRB) is experiencing strong investor confidence, with its stock price near a 52-week high and solid upward momentum indicated by moving averages [1][5]. Financial Performance - Earnings of W.R. Berkley grew by 27.8% over the last five years, outperforming the industry average of 18.9% [2]. - The Zacks Consensus Estimate for W.R. Berkley's 2025 earnings per share indicates a year-over-year increase of 2.9%, with revenues projected at $14.35 billion, reflecting a 6.1% improvement [9]. - Return on equity for the trailing 12 months was 19.6%, significantly higher than the industry's 8.3% [10]. Stock Performance - Shares of W.R. Berkley have gained 38.3% in the past year, outperforming the Finance sector and the Zacks S&P 500 composite, which grew by 15.9% and 8.3%, respectively [5][6]. Growth Strategy - W.R. Berkley is focusing on commercial lines, including excess and surplus lines, where it holds a competitive advantage [12]. - The company's insurance business is expected to grow due to new startup units, international expansion, rate increases, and high retention [13][14]. Valuation - W.R. Berkley shares are trading at a premium, with a price-to-book value of 3.08X compared to the industry average of 1.61X [15]. - The company has been consistently increasing dividends since 2005, with a dividend yield of 0.4%, which is attractive compared to the industry average of 0.2% [18].

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

Group 1 - Elanco Animal Health announced the sale of future tiered royalties and commercial milestones related to Xdemvy for $295 million in cash, aimed at accelerating debt reduction [1] - The proceeds from the sale will help Elanco achieve a net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end of 2025 [1] - Elanco plans to repay portions of its outstanding term loans, which is expected to reduce interest expenses by approximately $10 million [2] Group 2 - Xdemvy, the first lotilaner-based product approved for human use, addresses Demodex blepharitis and is licensed to Tarsus Pharmaceuticals for exploration of human health applications [3] - The agreement covers tiered royalties on Xdemvy's U.S. net sales from April 2025 through August 2033 [3] - Elanco retains rights to all royalty payments on net sales outside the U.S. and any future human applications of lotilaner beyond ophthalmic solutions [4] Group 3 - Elanco is scheduled to release its Q1 2025 financial results, with analysts expecting adjusted earnings per share of 31 cents and sales of $1.21 billion [4] - The current stock price of Elanco is $9.75, which is below the 200-day moving average of $12.34, indicating potential bearish sentiment [6] - Recent trading saw Elanco's stock decrease by 1.03% to $9.65 [7]

McDonald’s Corp MCD will report its first-quarter earnings on Thursday. Wall Street expects $2.66 in EPS and $6.09 billion in revenues as the company reports before market hours.The stock is up 16.11% over the past year, 8.38% year-to-date.Let’s examine the charts for McDonald’s stock and how it currently compares to Wall Street estimates.Read Also: Domino’s Pizza Earnings Miss: 3 ETFs That Could Still Deliver Tasty Returns In 2025MCD Stock Strongly Bullish Ahead Of Q1 EarningsChart created using Benzinga P ...

Eli Lilly And Co LLY will be reporting its first-quarter earnings on Thursday. Wall Street expects $3.05 in EPS and $12.67 billion in revenues as the company reports before market hours.The stock is up 14.35% over the past year, 14.79% YTD.Let’s examine the charts for Eli Lilly stock and how it currently compares to Wall Street estimates.Read Also: $1000 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayLLY Stock Chart Strongly Bullish Ahead Of Q1 EarningsChart created using Benzinga ProEli ...

Core Insights - Tesla Inc. has seen a significant increase in short interest, rising over 21% to 81.331 million shares, making it the fourth most shorted stock in the U.S. market [1][3][4] Short Interest and Trading Volume - The short interest increased from 67.126 million to 81.331 million shares, representing about 2.9% of the company's publicly available shares as of March 14 [1][2] - The short interest surged by 21.16% from the previous settlement date of February 28, with average daily trading volume rising from 84.714 million to 125.16 million shares [2] Market Sentiment - The increase in short interest indicates lower confidence among investors, as noted by tech analyst Beth Kindig [3] - Tesla's notional short interest is now the fourth-largest, following Nvidia, Microsoft, and Apple [4] Technical Analysis - Technical indicators suggest a bearish trend for Tesla's stock, which closed at $268.46, remaining below its 8, 50, and 200-day moving averages [4] - The relative strength index is at 47.30, indicating a neutral zone, while the MACD shows a bearish trend with a score of -11.6, although the histogram indicates a potential bullish sign within the bearish trend [5] Price Action - Tesla shares were down 1.37% in premarket trading, with a year-to-date decline of 29.22%, despite a 61.11% increase over the last year [6] Analyst Ratings - A consensus "hold" rating from 29 analysts suggests an average price target of $309.55, with a potential upside of 67.86% based on recent ratings from Stifel, Deutsche Bank, and Wedbush averaging $450 [8]